Johnson Fistel, PLLP is investigating Simulations Plus on behalf of investors who suffered losses. On June 11, 2025, Simulations Plus reduced its fiscal 2025 revenue guidance to a range of $76 million to $80 million from the prior $90 million to $93 million, citing budget reductions, project cancellations, and delays affecting pharmaceutical and biotechnology customers, which caused shares to decline more than 24%. In July 2025, the company reported a $67.3 million net loss that included a $77.2 million non-cash impairment charge and disclosed the dismissal of Grant Thornton LLP as its independent registered public accounting firm. Grant Thornton later informed the SEC that it had identified matters concerning segment reporting, reporting-unit determinations, and internal control over financial reporting that were not resolved to its satisfaction as of the termination date, after which Simulations Plus shares declined nearly 26%.
Simulations Plus IncRevenue guidance cut due to budget reductions, project cancellations, and delays from pharma/biotech customers.